These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 28618455)
1. Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice. Chong EW; Al-Qureshi SH Clin Exp Ophthalmol; 2017 May; 45(4):333-335. PubMed ID: 28618455 [No Abstract] [Full Text] [Related]
2. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Moon DRC; Lee DK; Kim SH; You YS; Kwon OW Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506 [TBL] [Abstract][Full Text] [Related]
3. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539 [TBL] [Abstract][Full Text] [Related]
4. Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Sagiv O; Zloto O; Moroz I; Moisseiev J Ophthalmologica; 2017; 238(4):217-225. PubMed ID: 28926846 [TBL] [Abstract][Full Text] [Related]
5. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators. Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385 [TBL] [Abstract][Full Text] [Related]
6. The relationship between vascular endothelial dysfunction and treatment frequency in neovascular age-related macular degeneration. Ueda-Consolvo T; Hayashi A; Ozaki M; Nakamura T; Yagou T; Abe S Jpn J Ophthalmol; 2017 Jul; 61(4):347-353. PubMed ID: 28447271 [TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor. Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037 [TBL] [Abstract][Full Text] [Related]
8. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Xu Y; Tan CS Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451 [TBL] [Abstract][Full Text] [Related]
9. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN. Rahimy E; Rayess N; Ho AC; Regillo CD Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316 [TBL] [Abstract][Full Text] [Related]
10. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850 [TBL] [Abstract][Full Text] [Related]
11. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration. Lee JY; Chung H; Kim HC Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631 [TBL] [Abstract][Full Text] [Related]
13. Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Stattin M; Forster J; Graf A; Ahmed D; Krebs I; Ansari-Shahrezaei S Acta Ophthalmol; 2019 Feb; 97(1):e131-e133. PubMed ID: 30281212 [No Abstract] [Full Text] [Related]
14. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537 [TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology. Bakri SJ; Thorne JE; Ho AC; Ehlers JP; Schoenberger SD; Yeh S; Kim SJ Ophthalmology; 2019 Jan; 126(1):55-63. PubMed ID: 30077616 [TBL] [Abstract][Full Text] [Related]
18. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Abedi F; Wickremasinghe S; Islam AF; Inglis KM; Guymer RH Retina; 2014 Aug; 34(8):1531-8. PubMed ID: 24637667 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity. Chang YS; Han JI; Yoo SJ; Lew YJ; Kim JH Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749 [TBL] [Abstract][Full Text] [Related]